Transformation of an Unclassified Myeloproliferative Neoplasm with a Rare BCR-JAK2 Fusion Transcript Resulting from the Translocation (9;22)(p24;q11)

Case Reports in Hematology
A N ChamseddineF Jardin

Abstract

BCR-ABL1 negative myeloproliferative neoplasms (MPNs) are known to contain alterations of the tyrosine kinase JAK2 (located on 9p24) that result in constitutive activation of the encoded protein. JAK2 fusions are reported in acute and chronic leukemias of myeloid and lymphoid phenotypes. Here, we report an unclassified case of MPN (MPN-U) showing a t(9;22)(p24;q11), which generates a BCR-JAK2 fusion gene by fusing the BCR at intron 13 to JAK2 at intron 17 on the derivative chromosome 22. Most reported JAK2 fusions cases reveal an aggressive clinical course and long-term remissions have only been achieved after allogeneic stem cell transplantation (ASCT). To the best of our knowledge, this is the thirteenth case reported worldwide to describe a BCR-JAK2 fusion transcript in MPN-U. The present report revealed a sustained complete clinical, hematologic, and cytogenetic remission 35 months after diagnosis and ~24 months after ASCT. Regarding BCR-ABL1  negative MPN patients this case report provides strong support for a role of JAK2 activation in the oncogenesis and suggests a possible diagnostic and therapeutic target that should be investigated.

References

Apr 11, 2003·Molecular Biology of the Cell·Pipsa SaharinenOlli Silvennoinen
May 28, 2008·Cancer Genetics and Cytogenetics·Gabriella CirmenaMario Sessarego
Jun 10, 2008·British Journal of Haematology·Steven W LaneGlen A Kennedy
Aug 7, 2008·Seminars in Cell & Developmental Biology·William VainchenkerStefan N Constantinescu
Aug 2, 2013·Revista brasileira de hematologia e hemoterapia·Marcelo BellessoRenata Campos Elias
Jun 14, 2014·The Journal of Biological Chemistry·Wenjing TaoRalph B Arlinghaus

❮ Previous
Next ❯

Citations

May 3, 2016·Cancer Genetics·Rong HeDavid S Viswanatha

❮ Previous
Next ❯

Methods Mentioned

BETA
bone marrow aspiration
PCR

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.